Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.62 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15114562 | 0.84 | GPR119 (0.68) | GPR119GPR183 | |
| SCHEMBL16705280 | 0.82 | GPR119 (0.66) | GPR119GPR183 | |
| SCHEMBL15931982 | 0.81 | GPR119 (0.64) | GPR119GPR183SMN1; SMN2 | |
| SCHEMBL15423133 | 0.78 | GPR119 (0.74) | GPR119GPR183SMN1; SMN2TDP1 | |
| SCHEMBL1128602 | 0.78 | GPR119 (0.60) | GPR119GPR183 | |
| SCHEMBL5779093 | 0.78 | GPR119 (0.74) | GPR119GPR183 | |
| SCHEMBL13195431 | 0.78 | GPR119 (0.74) | GPR119GPR183 | |
| SCHEMBL19450725 | 0.77 | GPR119 (0.72) | GPR119GPR183 | |
| SCHEMBL354846 | 0.77 | GPR119 (1.00) | GPR119GPR183ALOX5AP | |
| SCHEMBL461984 | 0.77 | GPR119 (0.72) | GPR119GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
| EP-4157263-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | The Regents Of The University Of Michigan (US) | 2023-04-05 | — | — | EP | disclosed |
| WO-2021242753-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-12-02 | — | — | WO | disclosed |
| EP-3207928-B1 | COMPOSITE PREPARATION, CONTAINING NOVEL 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE AND ANOTHER ACTIVE INGREDIENT, FOR PREVENTING OR TREATING METABOLIC DISEASES | HYUNDAI PHARM CO LTD (KR) | 2021-03-10 | — | — | EP | disclosed |
| US-10821110-B2 | Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases | HYUNDAI PHARM CO., LTD. (KR) | 2020-11-03 | — | — | US | disclosed |
| CN-106715409-B | Complex preparation for preventing or treating metabolic diseases comprising 3- (4- (benzyloxy) phenyl) -4-hexynoic acid derivative and other active ingredients | 现代药品株式会社 | 2020-09-11 | — | — | CN | disclosed |
| CN-111423408-A | Compound preparation for preventing or treating metabolic diseases | 现代药品株式会社 | 2020-07-17 | — | — | CN | disclosed |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| CN-105646492-A | Five-membered-aromatic-heterocycte-containing substituted xanthine compound and preparation method and use thereof | 中国医学科学院药物研究所 | 2016-06-08 | — | — | CN | disclosed |
| EP-2987791-A1 | NOVEL 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2016-02-24 | — | — | EP | disclosed |
| US-20160024063-A1 | NOVEL 3-(4(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT | HYUNDAI PHARM CO., LTD (KR) | 2016-01-28 | — | — | US | disclosed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
| US-8853213-B2 | Bicyclic compound for modulating G protein-coupled receptors | HANMI PHARM. CO., LTD (KR) | 2014-10-07 | — | — | US | disclosed |
| EP-2661438-A2 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | Hanmi Pharm. Co., Ltd. (KR) | 2013-11-13 | — | — | EP | disclosed |
| US-20130274268-A1 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | HANMI PHARM. CO., LTD (KR) | 2013-10-17 | — | — | US | disclosed |
| WO-2012093809-A2 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | HANMI PHARM CO., LTD. (KR) | 2012-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562869-B2 | Oxadiazole compounds | OXA1L, PSEN1, MAPT | GPR119 303/4885HRH1 1421/4885GPR183 2031/4885 |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | GPR119 441/4885HRH1 1580/4885GPR183 2154/4885 |
| US-20130274268-A1 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GPR119, GPR65, GPR3 | GPR119 1/4885HRH1 609/4885GPR183 18/4885 |
| US-20160024063-A1 | NOVEL 3-(4(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT | GPR119, INSR, IRS1 | GPR119 1/4885HRH1 1386/4885GPR183 610/4885 |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | GPR119 303/4885HRH1 1421/4885GPR183 2031/4885 |
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | TFAM, CS, FH | GPR119 197/4885HRH1 4599/4885GPR183 2423/4885 |
| US-10821110-B2 | Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases | SLC5A2, SLC5A1, DPP4 | GPR119 5/4885HRH1 3110/4885GPR183 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.